TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30348537
Drug: DPYD genotype-guided
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPYD genotype-guided dosing (initial dose reduction of 25% for c.2846A>T and c.1236G>A carriers, 50% for DPYD*2A and c.1679T>G carriers)
Study: 30348537
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (full dose fluoropyrimidine-based therapy)
Study: 30348537
Drug: Historical cohort
Normalized name: typhus, historical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Historical cohort (full dose fluoropyrimidine-based therapy)
Study: 30348638
Drug: SHR-1210 (anti-PD-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1210 (anti-PD-1 antibody) and apatinib (VEGFR2 inhibitor) combination therapy
Study: 30350179
Drug: Trifluridine/tipiracil (FTD/TPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil (FTD/TPI) 35 mg/m² during a 28-day treatment cycle
Study: 30351341
Drug: Hsp90 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hsp90 inhibitor luminespib (AUY922)
Study: 30352440
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) on
Study: 30352440
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI) off
Study: 30352576
Drug: HYP-RT with
Approvals — FDA: no, EMA: no, PMDA: no
Description: HYP-RT with concomitant CDDP (4 weekly cycles of 35 mg/m2)
Study: 30352608
Drug: FDG and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy
Study: 30352608
Drug: Concomitant chemo-radiotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemo-radiotherapy (reference treatment)
Study: 30352714
Drug: Postdischarge opioid
Normalized name: OPIOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postdischarge opioid prescription (median 225mg OMEQ)
Study: 30352941
Drug: Dalantercept (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalantercept (0.6 mg/kg subcutaneously every 3 weeks) plus Sorafenib (400 mg orally once daily)
Study: 30352941
Drug: Dalantercept (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalantercept (0.4 mg/kg subcutaneously every 3 weeks) plus Sorafenib (400 mg orally once daily)
Study: 30353044
Drug: Olaparib (Lynparza™)
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib (Lynparza™) maintenance monotherapy
Study: 30353806
Drug: Positive airway
Normalized name: VersaPAP Positive Airway Pressure Device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive airway pressure (PAP) treatment for 4 months
Study: 30353806
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PAP treatment)
Study: 30353806
Drug: PAP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAP treatment adherence in participants without obesity
Study: 30353817
Drug: Daily pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily pain in NCP group
Study: 30354636
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon treatment
Study: 30354645
Drug: Drug-Coated Balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-Coated Balloon
Study: 30354737
Drug: Appropriate secondary
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate secondary prevention treatment at discharge (dual antiplatelet therapy and moderate/high dose statins, new-P2Y12 inhibitors, ACE inhibitors/ARBs, beta-blockers as indicated)
Study: 30354737
Drug: Evidence-based treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatments at discharge
Study: 30355158
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299v (20 billion CFU) once daily for 6 weeks
Study: 30355158
Drug: Vancomycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (250 mg QID for 10 days)
Study: 30355795
Drug: Intravenous dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dextrose without any parenteral nutrition (PN)
Study: 30345376
Drug: Evidence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence of concurrent systemic disease
Study: 30358179
Drug: Increased dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased dose of nelfinavir during the third trimester
Study: 30358468
Drug: Eligibility for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligibility for UshStat® gene therapy
Study: 30359447
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 2g of azithromycin
Study: 30359909
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg/day) - Cohort 1 (C1)
Study: 30359909
Drug: Talazoparib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (1 mg/day) - Cohort 2 (C2)
Study: 30361262
Drug: Venetoclax (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400, 800, or 1200 mg daily) combined with decitabine (20 mg/m²)
Study: 30361262
Drug: Venetoclax (400,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax (400, 800, or 1200 mg daily) combined with azacitidine
Study: 30361296
Drug: Dopamine agonists
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonists before intervention
Study: 30361296
Drug: Levodopa/carbidopa slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/carbidopa slow-release formulation after 12 weeks
Study: 30361296
Drug: Control groups
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control groups (medicated and drug-naive)
Study: 30361296
Drug: Dopamine agonist
Normalized name: Dopamine agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine agonist withdrawal syndrome
Study: 30361875
Drug: Metronomic capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic capecitabine 500 mg PO TID (could be reduced to 500 mg QD) and exemestane 25 mg QD or letrozole 2.5 mg QD
Study: 30361875
Drug: Metronomic capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Metronomic capecitabine combined with aromatase inhibitors
Study: 30362288
Drug: Recombinant von
Normalized name: antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein Injection [Altuviiio]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant von Willebrand factor (rVWF) administered alone
Study: 30362948
Drug: Drug use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug use during sex reported (n = 6)
Study: 30363894
Drug: l-tyrosine 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-tyrosine 1,000 mg (500 mg 2× daily) for 7 days
Study: 30364428
Drug: VRC01 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: VRC01 (40 mg/kg)
Study: 30365452
Drug: TDF/FTC +
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC + DRV/r (once daily; 4 pills/day)
Study: 30365452
Drug: RAL +
Normalized name: Hydrocortisone Acetate/Lidocaine Hydrochloride 1%-5% Topical application Lotion [DERMACINRX LIDOTRAL + HYDROCORTISONE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAL + DRV/r (twice daily; 5 pills/day)
Study: 30366567
Drug: 1% testosterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% testosterone gel daily for 12 months
Study: 30366567
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel daily for 12 months
Study: 30366774
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily portion of fruits and vegetables
Study: 30368548
Drug: Piperacillin/tazobactam (4/0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin/tazobactam (4/0.5 g, tid) administered over 0.5 h
Study: 30370457
Drug: Aquablation for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquablation for <100 cc prostates
Study: 30370457
Drug: Aquablation for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquablation for >100 cc prostates
Study: 30370468
Drug: Tocilizumab monotherapy
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab monotherapy (8 mg/kg)
Study: 30370468
Drug: Tocilizumab combined
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab combined with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)
Study: 30371223
Drug: Warfarin with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin with SSRIs
Study: 30373683
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure control with medications
Study: 30373800
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) with limited sampling strategies (LSSs)
Study: 30374686
Drug: Bevacizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab (10 mg/kg, every 2 weeks) with temsirolimus (25 mg weekly)
Study: 30377191
Drug: Oral Carnitine
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Carnitine Challenge Test (OCCT)
Study: 30377537
Drug: Hatha yoga,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hatha yoga, implemented via twice weekly 60-min group-based classes for 12 weeks.
Study: 30377677
Drug: ω-3 supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: ω-3 supplement use
Study: 30380032
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care STEMI treatment including DAPT
Study: 30380386
Drug: Hu5F9-G4 (5F9)
Normalized name: human-bovine reassortant rotavirus strain G1 vaccine / human-bovine reassortant rotavirus strain G2 vaccine / human-bovine reassortant rotavirus strain G3 vaccine / human-bovine reassortant rotavirus strain G4 vaccine / human-bovine reassortant rotavirus strain P1A[8] vaccine Oral Suspension [RotaTeq]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hu5F9-G4 (5F9) antibody with rituximab
Study: 30381282
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (protein isolate powder, immunomodulation solution, carbohydrate loading)
Study: 30382017
Drug: D2-receptor availability
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: D2-receptor availability assessment
Study: 30382850
Drug: Ceramic implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceramic implants (PURE Ceramic Implant, Institut Straumann AG, Basel, Switzerland) with a diameter of 4.1 mm
Study: 30383140
Drug: Imatinib, 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib, 400 mg once daily, orally for 5 years
Study: 30383777
Drug: Benznidazole treatment
Normalized name: benznidazole
DrugBank: Benznidazole (DB11989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benznidazole treatment (TrG)
Study: 30384320
Drug: Post-commitment medication
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-commitment medication treatment
Study: 30385437
Drug: Antihyperglycaemic medication
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihyperglycaemic medication
Study: 30386824
Drug: MRgRT dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRgRT dose adaptation
Study: 30387050
Drug: Early 7-day
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early 7-day supplemental parenteral nutrition (SPN)
Study: 30388108
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 400 mg albendazole (ALB)
Study: 30389646
Drug: Monthly motivational
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly motivational phone calls by a trained nutritionist and weekly tailored text messages over a 12-month period (high intervention uptake)
Study: 30389649
Drug: Online integrated
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Online integrated treatment (8 weeks, 12 modules based on cognitive behavioral therapy and motivational interviewing)
Study: 30389649
Drug: Psychoeducational control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychoeducational control group (links to resources, access to full treatment after follow-up)
Study: 30390672
Drug: Anti-TNF-α treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-TNF-α treatment pre-operatively (n=18)
Study: 30391776
Drug: Vitamin K-antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K-antagonist (VKA)
Study: 30391805
Drug: Insulin receptor-related
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin receptor-related genes and dopamine regulation-related genes in the dlPFC
Study: 30391805
Drug: Insulin receptor-related
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin receptor-related genes and dopamine regulation-related genes in the hippocampus
Study: 30391805
Drug: Insulin receptor
Normalized name: Insulin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin receptor gene (INSR)
Study: 30391805
Drug: Insulin receptor
Normalized name: Insulin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin receptor substrate 1 and 2
Study: 30392735
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral ondansetron
Study: 30392813
Drug: Conventional therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapies (maximal surgical resection followed by adjuvant craniospinal irradiation and chemotherapy)
Study: 30393106
Drug: Glecaprevir/pibrentasvir (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (300 mg/120 mg) orally once daily for 8 weeks (for patients without cirrhosis) or 12 weeks (for patients with compensated cirrhosis)
Study: 30394678
Drug: Long-term combined
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term combined antiretroviral therapy (ART)
Study: 30395220
Drug: Inadequate perioperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inadequate perioperative prophylaxis in patients with established antibiotic treatment
Study: 30396014
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (H SC) 600 mg via handheld syringe
Study: 30396014
Drug: Subcutaneous trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous trastuzumab (H SC) 600 mg via single-use injection device
Study: 30396865
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg per day) added to simvastatin (40 mg per day)
Study: 30397066
Drug: Efavirenz-based antiretroviral
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz-based antiretroviral therapy without any efavirenz dose adjustments in children with TB/HIV coinfection.
Study: 30397066
Drug: Efavirenz-based antiretroviral
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz-based antiretroviral therapy without any efavirenz dose adjustments in children without TB.
Study: 30397067
Drug: WCK 5222
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WCK 5222 (Cefepime-Zidebactam Combination)
Study: 30398516
Drug: Higher baseline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher baseline sex hormone-binding globulin (SHBG) level among men
Study: 30398516
Drug: Sex steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex steroids
Study: 30399021
Drug: Lidocaine administration
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine administration (1.5 mg·kg bolus followed by 2 mg·kg·hour continuous infusion, then 1 mg·kg·hour after skin closure)
Study: 30400780
Drug: Ixazomib in
Normalized name: Product containing ixazomib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib in combination with carboplatin
Study: 30400834
Drug: Vaccine acceptance
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine acceptance predictors
Study: 30400864
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate sodium 70 mg plus vitamin D3 5600 IU once weekly for 26 weeks
Study: 30402565
Drug: Immediate compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate compression (weekly two-component compression bandages during chemotherapy)
Study: 30402565
Drug: Delayed compression
Normalized name: oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed compression (compression after chemotherapy)
Study: 30402678
Drug: Temsirolimus (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (20 mg or 25 mg IV weekly) + Bevacizumab (10 mg/kg every 2 weeks)
Study: 30403300
Drug: Cidofovir and
Normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cidofovir and intravenous immunoglobulin
Study: 30405743
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba pills
Study: 30408135
Drug: Total bilirubin
Normalized name: bilirubin preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total bilirubin ≥ 40 μmol/L
Study: 30408135
Drug: Leucocyte count
Normalized name: oteseconazole
DrugBank: Oteseconazole (DB13055)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucocyte count above 7x10(9)/L
Study: 30410313
Drug: Filgrastim (Nivestim™)
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Filgrastim (Nivestim™) administered at home
Study: 30410448
Drug: Moxonidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxonidine (0.2 mg daily initially, up titrated to 0.4 mg daily in 2 weeks)
Study: 30410720
Drug: Temsirolimus (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temsirolimus (20 mg/m)
Study: 30410781
Drug: domperidone (14-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: domperidone (14-day treatment)
Study: 30411246
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of hydroxyethyl starch (HES) solutions
Study: 30413378
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP1)
Study: 30413378
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP2-5)
Study: 30413378
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP2-3A)
Study: 30413378
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP3B)
Study: 30413378
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (EXP4-5)
Study: 30413378
Drug: Lorlatinib 100
Normalized name: lorlatinib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorlatinib 100 mg orally once daily continuously in 21-day cycles (all patients)
Study: 30413396
Drug: ASP8232 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8232 40 mg orally once daily for 12 weeks
Study: 30413396
Drug: ASP8232 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8232 40 mg
Study: 30413669
Drug: MBC-11 (0.5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MBC-11 (0.5-10 mg/kg per day, administered daily for 5 days of every 4 weeks for up to four cycles)
Study: 30413837
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg everolimus once daily + 50 mg CTX once daily
Study: 30414054
Drug: micro-fluid challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: micro-fluid challenge (micro-FC; rapid central infusion of 50 ml)
Study: 30414054
Drug: traditional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: traditional fluid challenge (FC; 5 ml/kg)
Study: 30414302
Drug: Decision to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision to reintroduce antiplatelet therapy
Study: 30415451
Drug: Golimumab (GLM)
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Golimumab (GLM) 50 mg subcutaneously (SC) monthly
Study: 30416770
Drug: Leukocyte levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leukocyte levels >10.5×10^9/L
Study: 30416787
Drug: Lung protective
Normalized name: beef lung preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lung protective strategy with low tidal volume (Vt) (≤8 mL/kg) and limitation of the plateau pressure (Pplat) (≤30 cmH2O)
Study: 30418357
Drug: Anidulafungin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anidulafungin (3 mg/kg on day 1, 1.5 mg/kg daily thereafter for 10-35 days)
Study: 30418358
Drug: Preferred site
Normalized name: SOLO SITE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preferred site for vaccine administration among HCPs
Study: 30418539
Drug: Oral broad-spectrum
Normalized name: Sentinel Spectrum Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral broad-spectrum antibiotics (ciprofloxacin, vancomycin, and metronidazole) for 7 days
Study: 30419887
Drug: Hydration therapy
Normalized name: Neosporin Daily Hydration Therapy SPF 20 Lip Balm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration therapy (drinking at least 2 L/day of hypotonic, oligomineral water low in sodium and minerals for at least 12 months)